id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
work_kqvusnyokvdxhceh6c5frdixs4	Purvish M. Parikh	P2-296: Treatment of advanced stage NSCLC with low dose gemcitabine and carboplatin in patients above age of 60 years	2007.0	1	.pdf	application/pdf	893	64	63	Treatment of advanced stage NSCLC with low dose gemcitabine and carboplatin in patients above age of 60 years: P2-296 Treatment of advanced stage NSCLC with low dose gemcitabine stage NSCLC is platinum doublet chemotherapy, one of the most active being Gemcitabineplatinum combination. more) having advanced stage NSCLC with low dose prolonged infusion Gemcitabine (350mg/m2 over 4 hours, Day 1 and Day 8) and standard dose Carboplatin (AUC-5, Day 1 only) repeated every 3 weeks for median overall survival was 11 months (range 1 34 months). were significant differences among patients treated by medical oncologists (group 1) and by others (group 2). Conclusions: We conclude that low dose prolonged infusion gemcitabine and standard carboplatin combination is an effective treatment for patients above the age of 60 years with advanced stage NSCLC. chemotherapy-naive patients with advanced non-small cell lung Conclusion: Weekly schedule of docetaxel and gemcitabine has modest activity in advanced NSCLC.	./cache/work_kqvusnyokvdxhceh6c5frdixs4.pdf	./txt/work_kqvusnyokvdxhceh6c5frdixs4.txt